{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T21:37:10Z","timestamp":1788903430007,"version":"build-2803163510"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,4,30]],"date-time":"2022-04-30T00:00:00Z","timestamp":1651276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,4,30]],"date-time":"2022-04-30T00:00:00Z","timestamp":1651276800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Gastric Cancer"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1007\/s10120-022-01300-1","type":"journal-article","created":{"date-parts":[[2022,4,30]],"date-time":"2022-04-30T08:03:30Z","timestamp":1651305810000},"page":"966-972","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Neoadjuvant docetaxel, oxaliplatin and S\u20111 (DOS) combination chemotherapy for patients with resectable adenocarcinoma of esophagogastric junction"],"prefix":"10.1007","volume":"25","author":[{"given":"Takuro","family":"Saito","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukinori","family":"Kurokawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsuyoshi","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuyoshi","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kotaro","family":"Yamashita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoki","family":"Makino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyokazu","family":"Nakajima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidetoshi","family":"Eguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichiro","family":"Doki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,4,30]]},"reference":[{"key":"1300_CR1","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1093\/jnci\/djn211","volume":"100","author":"LM Brown","year":"2008","unstructured":"Brown LM, Devesa SS, Chow WH. Incidence of adenocarcinoma of the esophagus among white americans by sex stage and age. J Natl Cancer Inst. 2008;100:1184\u20137.","journal-title":"J Natl Cancer Inst"},{"key":"1300_CR2","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1111\/j.1440-1746.2008.05572.x","volume":"23","author":"C Kusano","year":"2008","unstructured":"Kusano C, Gotoda T, Khor CJ, Katai H, Kato H, Taniguchi H, et al. Changing trends in the proportion of adenocarcinoma of the esophagogastric junction in a large tertiary referral center in Japan. J Gastroenterol Hepatol. 2008;23:1662\u20135.","journal-title":"J Gastroenterol Hepatol"},{"key":"1300_CR3","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1159\/000494406","volume":"99","author":"Y Imamura","year":"2018","unstructured":"Imamura Y, Watanabe M, Toihata T, Takamatsu M, Kawachi H, Haraguchi I, et al. Recent incidence trend of surgically resected esophagogastric junction adenocarcinoma and microsatellite instability status in Japanese patients. Digestion. 2018;99:6\u201313.","journal-title":"Digestion"},{"key":"1300_CR4","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s10120-014-0425-4","volume":"18","author":"S Olefson","year":"2015","unstructured":"Olefson S, Moss SF. Obesity and related risk factors in gastric cardia adenocarcinoma. Gastric Cancer. 2015;18:23\u201332.","journal-title":"Gastric Cancer"},{"key":"1300_CR5","doi-asserted-by":"publisher","first-page":"209","DOI":"10.5230\/jgc.2018.18.e28","volume":"18","author":"T Hashimoto","year":"2018","unstructured":"Hashimoto T, Kurokawa Y, Mori M, Doki Y. Surgical treatment of gastroesophageal junction cancer. J Gastric Cancer. 2018;18:209\u201317.","journal-title":"J Gastric Cancer"},{"key":"1300_CR6","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.surg.2014.08.099","volume":"157","author":"Y Kurokawa","year":"2015","unstructured":"Kurokawa Y, Hiki N, Yoshikawa T, Kishi K, Ito Y, Ohi M, et al. Mediastinal lymph node metastasis and recurrence in adenocarcinoma of the esophagogastric junction. Surgery. 2015;157:551\u20135.","journal-title":"Surgery"},{"key":"1300_CR7","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1097\/SLA.0000000000003499","volume":"274","author":"Y Kurokawa","year":"2021","unstructured":"Kurokawa Y, Takeuchi H, Doki Y, Mine S, Terashima M, Yasuda T, et al. Mapping of lymph node metastasis from esophagogastric junction tumors: a prospective nationwide multicenter study. Ann Surg. 2021;274:120\u20137.","journal-title":"Ann Surg"},{"key":"1300_CR8","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1002\/ags3.12406","volume":"5","author":"Y Imamura","year":"2021","unstructured":"Imamura Y, Watanabe M, Oki E, Morita M, Baba H. Esophagogastric junction adenocarcinoma shares characteristics with gastric adenocarcinoma: literature review and retrospective multicenter cohort study. Ann Gastroenterol Surg. 2021;5:46\u201359.","journal-title":"Ann Gastroenterol Surg"},{"key":"1300_CR9","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa055531","volume":"355","author":"C David","year":"2006","unstructured":"David C, William HA, Sally PS, Jeremy NT, Cornelis JH, Marianne N, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355:11\u201320.","journal-title":"N Engl J Med"},{"key":"1300_CR10","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1056\/NEJMoa072252","volume":"357","author":"S Sakuramoto","year":"2007","unstructured":"Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 2007;357:1810\u201320.","journal-title":"N Engl J Med"},{"key":"1300_CR11","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1200\/JCO.18.01138","volume":"37","author":"K Yoshida","year":"2019","unstructured":"Yoshida K, Kodera Y, Kochi M, Ichikawa W, Kakeji Y, Sano T, et al. Addition of docetaxel to oral fluoropyrimidine improves efficacy in patients with stage III gastric cancer: interim analysis of JACCRO GC-07, a randomized controlled trial. J Clin Oncol. 2019;37:1296\u2013304.","journal-title":"J Clin Oncol"},{"key":"1300_CR12","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/S0140-6736(11)61873-4","volume":"379","author":"YJ Bang","year":"2012","unstructured":"Bang YJ, Kim YW, Yang HK, Chung HC, Park YK, Lee KH, et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet. 2012;379:315\u201321.","journal-title":"Lancet"},{"key":"1300_CR13","doi-asserted-by":"publisher","first-page":"1948","DOI":"10.1016\/S0140-6736(18)32557-1","volume":"393","author":"SE Al-Batran","year":"2019","unstructured":"Al-Batran SE, Homann N, Pauligk C, Goetze TO, Meiler J, Kasper S, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2\/3 trial. Lancet. 2019;393:1948\u201357.","journal-title":"Lancet"},{"key":"1300_CR14","doi-asserted-by":"publisher","first-page":"2903","DOI":"10.1200\/JCO.20.02914","volume":"39","author":"Y-K Kang","year":"2021","unstructured":"Kang Y-K, Yook JH, Park Y-K, Lee JS, Kim Y-W, Kim JY, et al. PRODIGY: a phase III Study of neoadjuvant docetaxel, oxaliplatin, and S-1 plus surgery and adjuvant S-1 versus surgery and adjuvant S-1 for resectable advanced gastric cancer. J Clin Oncol. 2021;39:2903\u201313.","journal-title":"J Clin Oncol"},{"key":"1300_CR15","first-page":"1843","volume":"24","author":"K Yoshida","year":"2004","unstructured":"Yoshida K, Hirabayashi N, Takiyama W, Ninomiya M, Takakura N, Sakamoto J, et al. Phase I study of combination therapy with S-1 and docetaxel (TXT) for advanced or recurrent gastric cancer. Anticancer Res. 2004;24:1843\u201351.","journal-title":"Anticancer Res"},{"key":"1300_CR16","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1046\/j.1365-2168.1998.00940.x","volume":"85","author":"JR Siewert","year":"1998","unstructured":"Siewert JR, Stein HJ. Classification of adenocarcinoma of the oesophagogastric junction. Br J Surg. 1998;85:1457\u20139.","journal-title":"Br J Surg"},{"key":"1300_CR17","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1111\/dote.12540","volume":"29","author":"TW Rice","year":"2016","unstructured":"Rice TW, Ishwaran H, Blackstone EH, Hofstetter WL, Kelsen DP, Apperson-Hansen C, et al. Recommendations for clinical staging (cTNM) of cancer of the esophagus and esophagogastric junction for the 8th edition AJCC\/UICC staging manuals esophageal cancer staging recommendations: clinical. Dis Esophagus. 2016;29:913\u20139.","journal-title":"Dis Esophagus"},{"key":"1300_CR18","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1097\/01.sla.0000133083.54934.ae","volume":"240","author":"D Dindo","year":"2004","unstructured":"Dindo D, Demartines N, Clavien P-A. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240:205\u201313.","journal-title":"Ann Surg"},{"key":"1300_CR19","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1007\/s00595-015-1236-x","volume":"46","author":"H Katayama","year":"2016","unstructured":"Katayama H, Kurokawa Y, Nakamura K, Ito H, Kanemitsu Y, Masuda N, et al. Extended clavien-dindo classification of surgical complications: japan clinical oncology group postoperative complications criteria. Surg Today. 2016;46:668\u201385.","journal-title":"Surg Today"},{"key":"1300_CR20","doi-asserted-by":"crossref","unstructured":"Japanese classification of gastric carcinoma 3rd English edition. Gastric Cancer. 2011;14:101\u201312.","DOI":"10.1007\/s10120-011-0041-5"},{"key":"1300_CR21","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/S1470-2045(21)00297-7","volume":"22","author":"X Zhang","year":"2021","unstructured":"Zhang X, Liang H, Li Z, Xue Y, Wang Y, Zhou Z, et al. Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial. Lancet Oncol. 2021;22:1081\u201392.","journal-title":"Lancet Oncol"},{"issue":"suppl 3","key":"1300_CR22","doi-asserted-by":"publisher","first-page":"abstr 214","DOI":"10.1200\/JCO.2021.39.3_suppl.214","volume":"39","author":"Y Imamura","year":"2021","unstructured":"Imamura Y, Chin K, Tsushima T, Tsubosa Y, Hara H, Fukuda T, et al. Phase II study of systemic chemotherapy with S-1 plus oxaliplatin followed by surgery in patients with cT3-T4a and\/or node-positive advanced adenocarcinoma of the esophagogastric junction: Primary endpoint results of the ESOX trial. J Clin Oncol. 2021;39(suppl 3):abstr 214.","journal-title":"J Clin Oncol"},{"key":"1300_CR23","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1016\/S1470-2045(16)30531-9","volume":"17","author":"SE Al-Batran","year":"2016","unstructured":"Al-Batran SE, Hofheinz RD, Pauligk C, Kopp HG, Haag GM, Luley KB, et al. Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2\/3 trial. Lancet Oncol. 2016;17:1697\u2013708.","journal-title":"Lancet Oncol"},{"key":"1300_CR24","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/nature13480","volume":"513","author":"AJ Bass","year":"2014","unstructured":"Bass AJ, Thorsson V, Shmulevich I, Reynolds SM, Miller M, Bernard B, et al. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014;513:202\u20139.","journal-title":"Nature"},{"key":"1300_CR25","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1097\/SLA.0000000000002803","volume":"270","author":"YY Choi","year":"2019","unstructured":"Choi YY, Kim H, Shin SJ, Kim HY, Lee J, Yang HK, et al. Microsatellite instability and programmed cell death-ligand 1 expression in stage II\/III gastric cancer: post hoc analysis of the CLASSIC randomized controlled study. Ann Surg. 2019;270:309\u201316.","journal-title":"Ann Surg"},{"key":"1300_CR26","doi-asserted-by":"publisher","first-page":"3392","DOI":"10.1200\/JCO.19.01124","volume":"37","author":"F Pietrantonio","year":"2019","unstructured":"Pietrantonio F, Miceli R, Raimondi A, Kim YW, Kang WK, Langley RE, et al. Individual patient data meta-analysis of the value of microsatellite instability as a biomarker in gastric cancer. J Clin Oncol. 2019;37:3392\u2013400.","journal-title":"J Clin Oncol"},{"key":"1300_CR27","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1093\/jjco\/hyf057","volume":"32","author":"YJ Bang","year":"2002","unstructured":"Bang YJ, Kang WK, Kang YK, Kim HC, Jacques C, Zuber E, et al. Docetaxel 75 mg\/m2 is active and well tolerated in patients with metastatic or recurrent gastric cancer: a phase II trial. Jpn J Clin Oncol. 2002;32:248\u201354.","journal-title":"Jpn J Clin Oncol"},{"key":"1300_CR28","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1007\/s10120-016-0619-z","volume":"20","author":"S Ito","year":"2017","unstructured":"Ito S, Sano T, Mizusawa J, Takahari D, Katayama H, Katai H, et al. A phase II study of preoperative chemotherapy with docetaxel, cisplatin, and S-1 followed by gastrectomy with D2 plus para-aortic lymph node dissection for gastric cancer with extensive lymph node metastasis: JCOG1002. Gastric Cancer. 2017;20:322\u201331.","journal-title":"Gastric Cancer"}],"container-title":["Gastric Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10120-022-01300-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10120-022-01300-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10120-022-01300-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,30]],"date-time":"2023-04-30T00:02:13Z","timestamp":1682812933000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10120-022-01300-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,30]]},"references-count":28,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["1300"],"URL":"https:\/\/doi.org\/10.1007\/s10120-022-01300-1","relation":{},"ISSN":["1436-3291","1436-3305"],"issn-type":[{"value":"1436-3291","type":"print"},{"value":"1436-3305","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,30]]},"assertion":[{"value":"19 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Yukinori Kurokawa and Yuichiro Doki have received research funding and lecture fees from Taiho Pharmaceutical and Yakult Honsha outside of the submitted work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki Declaration and its later amendments.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Written informed consent was obtained from all patients before treatment. Consent to participate in this retrospective study was not considered necessary.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}